Browsing by Author "Cetiner, Mustafa"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Complete Remission of Burkitt Lymphoma After Surgical Excision: A Case Report
    (SPRINGER INDIA, 2016-01-01) Bekoz, Huseyin Saffet; Kantarcioglu, Bulent; Tecimer, Tulay; Uskent, Necdet; Cetiner, Mustafa; Ferhanoglu, Burhan; Sargin, Deniz
    Burkitt lymphoma (BL) is a highly aggressive B cell non-Hodgkin lymphoma that has a high proliferation rate. The prognosis for BL is generally favorable, with cure rate of 75-90 \% with modern chemoimmunotherapy regimens. Prompt administration of multiagent immunochemotherapy regimens is critical, because BL is almost always fatal if left untreated. Nevertheless here we report a case of BL that is still in complete remission after more than 4 years without any further treatment after surgical excision of the involved lymph node.
  • Thumbnail Image
    Item
    Gastrostomy in Hospitalized Patients with Acute Stroke: ``NoroTek'' Turkey Point Prevalence Study Subgroup Analysis
    (GALENOS PUBL HOUSE, 2022-01-01) Topcuoglu, Mehmet Akif; Ozdemir, Atilla Ozcan; Aykac, Ozlem; Milanoglu, Aysel; Gokce, Mustafa; Bavli, Songul; Cabalar, Murat; Yayla, Vildan; Erdogan, Haci Ali; Ozkul, Ayca; Gunes, Aygul; Degirmenci, Bahar; Aluclu, Ufuk; Kozak, Hasan Huseyin; Gungor, Levent; Erdogan, Mucahid; Acar, Zeynep Ozdemir; Cenikli, Utku; Kablan, Yuksel; Yilmaz, Arda; Genc, Hamit; Nazliel, Bijen; Caglayan, Hale Batur; Gencer, Elif Sarionder; Ay, Halil; Demirbas, Hayri; Akdogan, Ozlem; Emre, Ufuk; Yildiz, Ozlem Kayim; Bolayir, Asli; Demir, Turgay; Tanriverdi, Zeynep; Tekan, Ulgen Yalaz; Akpinar, Cetin Kursad; Ozkan, Esra; Ilik, Faik; Sirin, Hadiye; Guler, Ayse; Onder, Halil; Bektas, Hesna; Ocek, Levent; Bakar, Mustafa; Ongun, Nedim; Krespi, Yakup; Isikay, Canan Togay; Aslanbaba, Eda; Sorgun, Mine; Gurkas, Erdem; Karadeli, Hasan Huseyin; Midi, Ipek; Ilgezdi, Irem; Bilgic, Adnan Burak; Akyol, Sener; Epceliden, M. Tuncay; Atmaca, Murat Mert; Kursun, Oguzhan; Keskin, Onur; Sirinocak, Pinar Bekdik; Baydemir, Recep; Akcakoyunlu, Merve; Ozturk, Serefnur; Ozel, Tugba; Unal, Ali; Dora, Babur; Yurekli, Vedat Ali; Arlier, Zulfikar; Eren, Alper; Yilmaz, Ayse; Kisabay, Aysin; Acar, Bilgehan; Bastan, Birgul; Acar, Zeynep; Niflioglu, Buket; Guven, Bulent; Kaya, Dilaver; Afsar, Nazire; Yazici, Duran; Aytac, Emrah; Yaka, Erdem; Toplutas, Eren; Degirmenci, Eylem; Ince, Fatma Birsen; Buyukserbetci, Gulseren; Aydin, Isa; Cetiner, Mustafa; Sen, Mustafa; Turgut, Nilda; Kale, Nilufer; Coban, Eda; Yesilot, Nilufer; Ekizoglu, Esme; Kizek, Ozgu; Birgili, Ozlem; Yevgi, Recep; Kunt, Refik; Giray, Semih; Akkas, Sinem Yazici; Senadim, Songul; Yoldas, Tahir; Asil, Talip; Duman, Taskin; Atasoy, Tugrul; Cinar, Bilge Piri; Demir, Tulin; Can, Ufuk; Unsal, Yaprak Ozum; Eskut, Neslihan; Aslan, Yildiz; Bas, Demet Funda; Sener, Ufuk; Yilmaz, Zahide; Bozdogan, Zehra; Alioglu, Zekeriya; Arsava, Ethem Murat
    Objective: Nutritional status assessment, dysphagia evaluation and enteral feeding decision are important determinants of prognosis in acute neurovascular diseases. Materials and Methods: NoroTek is a point prevalence study conducted with the participation of 87 hospitals spread across all health sub regions of Turkey conducted on 10-May-2018 (World Stroke Awareness Day). A total of 972 hospitalized neurovascular patients {[}female: 53\%, age: 69 +/- 14
  • Thumbnail Image
    Item
    GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro
    (OXFORD UNIV PRESS, 2015-01-01) Bildik, Gamze; Akin, Nazli; Senbabaoglu, Filiz; Sahin, Gizem Nur; Karahuseyinoglu, Sercin; Ince, Umit; Taskiran, Cagatay; Selek, Ugur; Yakin, Kayhan; Guzel, Yilmaz; Ayhan, Cem; Alper, Ebru; Cetiner, Mustafa; Balaban, Basak; Mandel, Nil Molinas; Esen, Tarik; Iwase, Akira; Urman, Bulent; Oktem, Ozgur
    STUDY QUESTION: Is there any in vitro evidence for or against ovarian protection by co-administration of a GnRH agonist with chemotherapy in human? SUMMARY ANSWER: The co-administration of GnRH agonist leuprolide acetate with cytotoxic chemotherapy agents does not preserve ovarian reserve in vitro. WHAT IS KNOWN ALREADY: Randomized controlled trials of the co-administration of gonadotrophin-releasing hormone (GnRH) agonists with adjuvant chemotherapy to preserve ovarian function have shown contradictory results. This fact, together with the lack of a proven molecular mechanism of action for ovarian protection with GnRH agonist (GnRHa) places this approach as a fertility preservation strategy under scrutiny. We therefore aimed in this study to provide in vitro evidence for or against the role of GnRHa in the prevention of chemotherapy-induced damage in human ovary. STUDY DESIGN, SETTINGS, SIZE AND DURATION: This translational research study of ex vivo and in vitro models of human ovary and granulosa cells was conducted in a university hospital between 2013 and 2015. PARTICIPANTS/MATERIALS, SETTING, METHODS: Ovarian cortical pieces (n = 15, age 14-37) and mitotic non-luteinized (COV434 and HGrC1) and non-mitotic luteinized human granulosa cells (HLGC) expressing GnRH receptor were used for the experiments. The samples were treated with cyclophosphamide, cisplatin, paclitaxel, 5-FU, or TAC combination regimen (docetaxel, adriamycin and cyclophosphamide) with and without GnRHa leuprolide acetate for 24 h. DNA damage, apoptosis, follicle reserve, hormone markers of ovarian function and reserve (estradiol (E2), progesterone (P) and anti-mullerian hormone (AMH)) and the expression of anti-apoptotic genes (bcl-2, bcl-xL, bcl-2L2, Mcl-1, BIRC-2 and XIAP) were compared among control, chemotherapy and chemotherapy + GnRHa groups. MAIN RESULTS AND THE ROLE OF CHANCE: The greatest magnitude of cytotoxicity was observed in the samples treated with cyclophosphamide, cisplatin and TAC regimen. Exposure to these drugs resulted in DNA damage, apoptosis and massive follicle loss along with a concurrent decline in the steroidogenic activity of the samples. GnRHa co-administered with chemotherapy agents stimulated its receptors and raised intracellular cAMP levels. But it neither activated anti-apoptotic pathways nor prevented follicle loss, DNA damage and apoptosis induced by these drugs. LIMITATIONS, REASONS FOR CAUTION: Our findings do not conclusively rule out the possibility that GnRHa may offer protection, if any, through some other mechanisms in vivo. WIDER IMPLICATIONS OF THE FINDINGS: GnRH agonist treatment with chemotherapy does not prevent or ameliorate ovarian damage and follicle loss in vitro. These data can be useful when consulting a young patient who may wish to receive GnRH treatment with chemotherapy to protect her ovaries from chemotherapy-induced damage.